Trial intelligence / Profile preview

Pasireotide plus aspiration sclerotherapy for dominant hepatic cysts

2013-003168-29Phase 3Completed

Sponsor: Radboud University Medical Center
Start: Aug 2013
Modality: Small Molecules, Peptides
Countries: 1

Overview

Phase 3, randomised, double-blind trial in hepatic cyst comparing Pasireotide LAR + aspiration sclerotherapy with Placebo + aspiration sclerotherapy (2 arms). Primary endpoint: Proportional change in cyst diameter at 4 weeks. Started Aug 2013; status: completed.

Drugs

pasireotide LAR

Conditions

hepatic cyst

Beyond the preview

Go deeper on 2013-003168-29.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-003168-29.